Early experience with remdesivir in SARS-CoV-2 pneumonia.

At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China in December 2019, causing severe pneumonia and acute respiratory distress syndrome [1]. Over the following few months, infection spread worldwide and WHO declared the status of a pandemic in March 11, 2020.

Currently, no definitive antiviral treatment for coronavirus disease 2019 (COVID-19) has been identified. Lopinavir/ritonavir (LPV/r) combination was not effective in adult patients with severe COVID-19 [2]. Hydroxychloroquine (HCQ) exhibits a consistent inhibitory activity on SARS-CoV-2 in vitro [3] and has shown promising results in a small cohort of patients with different severity of disease [4]. Remdesivir (RDV), a newer nucleotide analogue RNA polymerase inhibitor, originally developed for Ebola virus disease, shows in vitro efficacy against coronaviruses, including SARS-CoV-2 [5]. Recent clinical data on the efficacy and safety of RDV for COVID-19 have been published [6]. Thus, while clinical trials are ongoing, additional experience can be derived from initial COVID-19 cases treated with RDV.

We describe our early clinical experience with the use of RDV in four COVID-19 patients admitted to the Monaldi Hospital, Naples, Italy, in March 2020, because of severe pneumonia and respiratory distress. Treatment was given in the context of a compassionate use program approved by EMA and our Institution Ethics Committee. All patients had been previously treated with LPV/r or darunavir/cobicistat (DRV/c) and also received hydroxychloroquine, as per current Italian clinical recommendations.

Figure 1 summarizes the major clinical, biochemical and virological data of these four patients during their hospitalization. Antivirals administered and the results of SARS-CoV-2 RNA testing on nasal swabs are also shown. APACHE II score, pneumonia severity index and multiple organ dysfunction scores changed during treatment according to the individual patient response, as depicted in Fig. 1.

Fig. 1

Dynamics of C-reactive protein (CRP), lymphocyte count and ratio between partial oxygen pressure (PaO2) and inspired fraction of oxygen (FiO2) in the four patients treated with remdesivir. Antiviral agents administered are shown in the colored boxes for the pertinent time of therapy. The results of SARS-CoV-2 RNA testing on nasal swabs are shown with + and - signs. Time of ICU stay is shown by the blue bar. Changes in major acute physiology and organ function assessment scores before and after remdesivir administration are also shown. LPV/r, lopinavir/ritonavir; DRV/c, darunavir/cobicistat; HCQ, hydroxychloroquine; RDV, remdesivir; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; APACHE, Acute Physiology and Chronic Health Evaluation Score; PSI, pulmonary severity index; MODS, Multiple Organ Dysfunction Score

Patients received HCQ (200 mg twice daily po) and LPV/r (400/100 mg twice daily po) for a variable number of days as indicated in Fig. 1. Two patients had to switch from LPV/r to DRV/c (800/150 mg once daily po) due to shortage of the former drug. Of note, before RDV was initiated, all other antivirals were stopped. However, HCQ was restarted in combination with RDV in three patients. RDV was given as a 200 mg loading dose on day 1, followed by 100 mg daily as intravenous infusion over 1 h.

RDV was prematurely discontinued in patient 1 because of a torsade de pointes requiring cardiac resuscitation and in patient 3 because of death due to multiple organ failure. In patient 1, QT prolongation was observed after arrhythmia resolution. This patient survived and is currently improving outside of the intensive care unit. Patients 1, 2 and 3 also experienced both ALT and AST increase, ranging from 5 to 8 times the upper normal limit.

Lymphocyte count increased in all patients after RDV treatment start. However, the four patients also received tocilizumab, 800 mg intravenous infusion in the days immediately preceding RDV start (Fig. 1).

Nasal swab SARS-CoV-2 RNA became negative in three of four RDV-treated patients (Fig. 1). However, in patient 1 SARS-CoV-2 RNA test reverted to positive after RDV discontinuation. Thus, a shorter course of RDV correlated to a transient viral suppression, whereas a longer course translated into a seemingly more stable viral clearance. Patient 3 did not repeat nasal swab before dying.

Our study is limited by the low number of subjects included and the heterogeneity of treatments received before and during RDV administration. Notwithstanding, in the absence of large trials, our early experience may be relevant for other clinicians caring for COVID-19 patients.

In conclusion, we provide preliminary evidence for a clinically relevant, in vivo virological effect of RDV against SARS-CoV-2. Nasal viral load had remained persistently positive in these critically ill patients despite treatment with either LPV/r or DRV/c combined with HCQ. Although previously treated also with tocilizumab, three of our four critically ill COVID-19 patients experienced a clear clinical improvement on RDV treatment. However, initiation of this drug in combination with HCQ also translated into a significant burden of adverse events, requiring close monitoring. Larger studies are clearly warranted and strongly awaited to confirm RDV safety and effectiveness for COVID-19.

Availability of data and material (data transparency)

All data are available from hospital files, electronic medical records as well as the Medidata electronic data capturing system for remdesivir compassionate use.